A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
Clinical trial NCT04813796 · COMPLETED
Trial details
- NCT number
- NCT04813796
- Sponsor
- ModernaTX, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-11
- Primary completion
- 2023-07-25
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.